Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Prov...
August 06 2020 - 1:45PM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced that it will
host a conference call to discuss its Q2 2020 financial results and
provide a business update at 8:30 a.m. on Friday, August 14, 2020.
The company will issue a pre-market earnings
announcement the same day. Investors are invited to participate on
the call using the following details:
|
Dial-In Number: |
(844) 873-7330 (U.S.) or (602) 563-8473 (international) |
|
Conference
ID: |
ID 5587104 |
|
Webcast: |
Available in the “Investors”
section of the Ocugen website at https://ir.ocugen.com/ and
archived for approximately 45 days following the call |
About Ocugen, Inc.Ocugen, Inc. is
a biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
https://ocugen.com/.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen,
Inc.Sanjay SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact:
LaVoieHealthScienceEmmie Twomblyetwombly@lavoiehealthscience.com+1
857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024